Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03873714 · ClinicalTrials.gov registry record · NA
Pipeline™ Vantage Embolization Device With Shield Technology™ for Wide-Necked Intracranial Aneurysms (ADVANCE)
A NA study, sponsored by Medtronic Neurovascular Clinical Affairs.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT03873714: Clinical Trial NA study, sponsored by Medtronic Neurovascular Clinical Affairs.
NCT03873714 is a NA study that was terminated before completion, run by Medtronic Neurovascular Clinical Affairs. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03873714, a NA study, was terminated before completion, sponsored by Medtronic Neurovascular Clinical Affairs.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and effectiveness of the Pipeline™ Vantage Embolization Device with Shield Technology™ in the treatment of intracranial aneurysms within the intended indication for use.
Primary Outcome
Incidence of major stroke in the territory supplied by the treated artery or neurological death.
Interventions
- DEVICE Pipeline™ Vantage Embolization Device with Shield Technology™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-04-02 |
| Est. Completion | 2023-09-18 |
| Phase | NA |
Why NCT03873714 stopped before completion
NCT03873714 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Pipeline™ Vantage Embolization Device with Shield Technology™ is the first listed.
NCT03873714 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03873714 about?
NCT03873714 is a clinical study titled "Pipeline™ Vantage Embolization Device With Shield Technology™ for Wide-Necked Intracranial Aneurysms (ADVANCE)". The purpose of this study is to assess the safety and effectiveness of the Pipeline™ Vantage Embolization Device with Shield Technology™ in the treatment of intracranial aneurysms within the intended indication for use.
What is the current status of trial NCT03873714?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2020-04-02. Estimated completion is 2023-09-18.
What interventions are being tested in trial NCT03873714?
The interventions under investigation include: Pipeline™ Vantage Embolization Device with Shield Technology™ (DEVICE).
Who is sponsoring clinical trial NCT03873714?
This trial is sponsored by Medtronic Neurovascular Clinical Affairs, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03873714's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy